(αS)-α-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
| Title | Journal |
|---|---|
| Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice. | Journal of biochemical and molecular toxicology 20170401 |
| Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer. | Chemico-biological interactions 20161025 |
| Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes. | Toxicology 20160415 |
| Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. | Chemistry & biology 20150618 |
| Suppression of BRCA1 sensitizes cells to proteasome inhibitors. | Cell death & disease 20141201 |
| Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma. | Chemico-biological interactions 20140525 |
| Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. | Bone 20140401 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Carfilzomib. | Blood 20130207 |
| Molecular mechanisms of acquired proteasome inhibitor resistance. | Journal of medicinal chemistry 20121213 |
| Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma. | Drugs 20121022 |
| Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121015 |
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. | Blood 20121004 |
| Carfilzomib in multiple myeloma: gold, silver, or bronze? | Blood 20121004 |
| An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. | Clinical lymphoma, myeloma & leukemia 20121001 |
| A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120901 |
| An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. | British journal of haematology 20120901 |
| Emerging biological insights and novel treatment strategies in multiple myeloma. | Expert opinion on emerging drugs 20120901 |
| Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective. | Advances in chronic kidney disease 20120901 |
| Carfilzomib in multiple myeloma. | Clinical advances in hematology & oncology : H&O 20120901 |
| A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. | Blood 20120830 |
| Proteasome inhibitors in multiple myeloma: 10 years later. | Blood 20120802 |
| Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs. | Expert opinion on investigational drugs 20120801 |
| Role of carfilzomib in the treatment of multiple myeloma. | Expert review of hematology 20120801 |
| The immunoproteasome as a target in hematologic malignancies. | Seminars in hematology 20120701 |
| The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. | Seminars in hematology 20120701 |
| An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. | Blood 20120614 |
| Proteasome inhibitors in mantle cell lymphoma. | Best practice & research. Clinical haematology 20120601 |
| Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. | Molecular cancer therapeutics 20120501 |
| Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. | The oncologist 20120501 |
| Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. | The Journal of pharmacology and experimental therapeutics 20120401 |
| Novel therapeutics in multiple myeloma. | Hematology (Amsterdam, Netherlands) 20120401 |
| Novel therapies in monoclonal gammopathies. | Hematology (Amsterdam, Netherlands) 20120401 |
| Targeted therapy of multiple myeloma. | Hematology (Amsterdam, Netherlands) 20120401 |
| Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. | Arthritis and rheumatism 20120201 |
| The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201 |
| Next-generation proteasome blockers promise safer cancer therapy. | Nature medicine 20120106 |
| Ovarian cancer: opportunity for targeted therapy. | Journal of oncology 20120101 |
| Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies. | Methods in molecular biology (Clifton, N.J.) 20120101 |
| Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells. | PloS one 20120101 |
| Novel therapies for aggressive B-cell lymphoma. | Advances in hematology 20120101 |
| On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. | PloS one 20120101 |
| Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. | Advances in hematology 20120101 |
| Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. | OncoTargets and therapy 20120101 |
| Drugs: More shots on target. | Nature 20111214 |
| Advances in the understanding of mechanisms and therapeutic use of bortezomib. | Discovery medicine 20111201 |
| Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. | Drug metabolism and disposition: the biological fate of chemicals 20111001 |
| Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. | Blood 20110929 |
| Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. | Molecular cancer therapeutics 20110901 |
| [Development of novel agents for multiple myeloma; now and the future]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801 |
| Novel proteasome inhibitors to overcome bortezomib resistance. | Journal of the National Cancer Institute 20110706 |
| A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. | Nature genetics 20110619 |
| How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. | Expert opinion on investigational drugs 20110601 |
| Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. | European journal of haematology 20110601 |
| Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. | Chemistry & biology 20110527 |
| Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110501 |
| Carfilzomib: a novel second-generation proteasome inhibitor. | Future oncology (London, England) 20110501 |
| RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. | Blood 20110407 |
| Recent advances in myeloma treatment. | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20110401 |
| Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110401 |
| Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). | Current cancer drug targets 20110301 |
| Unfolded protein response in cancer: the physician's perspective. | Journal of hematology & oncology 20110101 |
| Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. | Molecular cancer 20110101 |
| Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. | Core evidence 20110101 |
| Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. | Journal of biomedicine & biotechnology 20110101 |
| Light chain (AL) amyloidosis: update on diagnosis and management. | Journal of hematology & oncology 20110101 |
| Molecular mechanisms of bortezomib resistant adenocarcinoma cells. | PloS one 20110101 |
| Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. | Investigational new drugs 20101201 |
| New twists on proteasome inhibitors. | Nature biotechnology 20101201 |
| Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. | The Biochemical journal 20100915 |
| Novel disease targets and management approaches for diffuse large B-cell lymphoma. | Leukemia & lymphoma 20100801 |
| Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. | Leukemia & lymphoma 20100701 |
| The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. | Blood 20100603 |
| Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70. | PLoS genetics 20100101 |
| Bortezomib. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101 |
| Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. | Current topics in medicinal chemistry 20100101 |
| State-of-the-Art Management of Complications of Myeloma and Its Treatment. | Advances in hematology 20100101 |
| Proteasome inhibition and its therapeutic potential in multiple myeloma. | Biologics : targets & therapy 20100101 |
| Relapsed multiple myeloma. | Hematology. American Society of Hematology. Education Program 20100101 |
| Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference. | IDrugs : the investigational drugs journal 20091201 |
| A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091115 |
| Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. | Leukemia 20091101 |
| Proteasome inhibitors in the treatment of multiple myeloma. | Leukemia 20091101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091101 |
| Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. | Blood 20091015 |
| Clinical development of novel proteasome inhibitors for cancer treatment. | Expert opinion on investigational drugs 20090701 |
| Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). | Journal of medicinal chemistry 20090514 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090401 |
| Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. | Cardiovascular & hematological disorders drug targets 20090301 |
| New drugs in multiple myeloma and the significance of autologous stem cell transplants. | Clinical advances in hematology & oncology : H&O 20090301 |
| Novel therapies for relapsed myeloma. | Hematology. American Society of Hematology. Education Program 20090101 |
| Future novel single agent and combination therapies. | Cancer journal (Sudbury, Mass.) 20090101 |
| Discovery of novel proteasome inhibitors using a high-content cell-based screening system. | PloS one 20090101 |
| The development and pharmacology of proteasome inhibitors for the management and treatment of cancer. | Advances in pharmacology (San Diego, Calif.) 20090101 |
| Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. | Core evidence 20090101 |
| The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. | Blood 20081001 |
| Practical considerations for multiple myeloma: an overview of recent data and current options. | Clinical lymphoma & myeloma 20080801 |
| Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. | Blood 20080601 |
| The potential of proteasome inhibitors in cancer therapy. | Expert opinion on investigational drugs 20080601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080301 |
| Mechanisms of proteasome inhibitor action and resistance in cancer. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20080101 |
| Targeting the UPS as therapy in multiple myeloma. | BMC biochemistry 20080101 |
| Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. | Blood 20071101 |
| Epoxomicin, a new antitumor agent of microbial origin. | The Journal of antibiotics 19921101 |